GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » Additional Paid-In Capital

Acepodia (ROCO:6976) Additional Paid-In Capital : NT$4,735.98 Mil(As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Acepodia Additional Paid-In Capital?


Acepodia's quarterly additional paid-in capital declined from Jun. 2023 (NT$4,748.75 Mil) to Dec. 2023 (NT$4,748.75 Mil) but then stayed the same from Dec. 2023 (NT$4,748.75 Mil) to Jun. 2024 (NT$4,735.98 Mil).

Acepodia's annual additional paid-in capital increased from Dec. 2021 (NT$104.39 Mil) to Dec. 2022 (NT$200.70 Mil) and increased from Dec. 2022 (NT$200.70 Mil) to Dec. 2023 (NT$4,748.75 Mil).


Acepodia Additional Paid-In Capital Historical Data

The historical data trend for Acepodia's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acepodia Additional Paid-In Capital Chart

Acepodia Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
- 104.39 200.70 4,748.75

Acepodia Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial - 200.70 4,748.75 4,748.75 4,735.98

Acepodia Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Acepodia Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Acepodia's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Acepodia Business Description

Industry
Traded in Other Exchanges
N/A
Address
17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175
Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia Headlines

No Headlines